¿Cuáles son los motivos del aumento de la incidencia? | 16 FEB 20

Cáncer de tiroides

Revisión de los factores relacionados con la epidemia de cáncer de tiroides.
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

[1] L. Davies and H. G. Welch, “Current thyroid cancer trends in the United States,” JAMA Otolaryngology. Head & Neck Surgery, vol. 140, no. 4, pp. 317–322, 2014.

[2] W. Chen, R. Zheng, P. D. Baade et al., “Cancer statistics in China, 2015,” CA: a Cancer Journal for Clinicians, vol. 66, no. 2, pp. 115–132, 2016.

[3] L. Dal Maso, M. Lise, P. Zambon et al., “Incidence of thyroid cancer in Italy, 1991-2005: time trends and age-period-cohort effects,” Annals of Oncology, vol. 22, no. 4, pp. 957–963, 2011.

[4] C. C. Lubitz, C. Y. Kong, P. M. McMahon et al., “Annual financial impact of well-differentiated thyroid cancer care in the United States,” Cancer, vol. 120, no. 9, pp. 1345–1352,2014.

[5] S. Cong, L. W. Fang, H. L. Bao et al., “Disease burden of thyroid cancer in the Chinese population, in 1990 and 2013,” Zhonghua Liu Xing Bing Xue Za Zhi, vol. 37, no. 6, pp. 773–777, 2016.

[6] R. Elisei, “Molecular profiles of papillary thyroid tumors have been changing in the last decades: how could we explain it?” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 2, pp. 412–414, 2014.

[7] L. Davies, L. G. Morris, M. Haymart et al., “American Association of Clinical Endocrinologists and American College of Endocrinology disease state clinical review: the increasing incidence of thyroid cancer,” Endocrine Practice, vol. 21,no. 6, pp. 686–696, 2015.

[8] Y. Ito, Y. E. Nikiforov, M. Schlumberger, and R. Vigneri, “Viewpoint: increasing incidence of thyroid cancer: controversies explored,” Nature Reviews Endocrinology, vol. 9,no. 3, pp. 178–184, 2013.

[9] R. Vigneri, P. Malandrino, and P. Vigneri, “The changing epidemiology of thyroid cancer: why is incidence increasing?” Current Opinion in Oncology, vol. 27, no. 1, pp. 1–7, 2015.

[10] C. M. Kitahara and J. A. Sosa, “The changing incidence of thyroid cancer,” Nature Reviews. Endocrinology, vol. 12,no. 11, pp. 646–653, 2016.

[11] H. S. Ahn, H. J. Kim, and H. G. Welch, “Korea’s thyroidcancer “epidemic”—screening and overdiagnosis,” The New England Journal of Medicine, vol. 371, no. 19, pp. 1765–1767, 2014.

[12] H. S. Ahn and H. G. Welch, “South Korea’s thyroid-cancer “epidemic”—turning the tide,” The New England Journal of Medicine, vol. 373, no. 24, pp. 2389–2390, 2015.

[13] B. L. Sprague, S. W. Andersen, and A. Trentham-Dietz, “Thyroid cancer incidence and socioeconomic indicators of health care access,” Cancer Causes & Control, vol. 19, no. 6, pp. 585–593, 2008.

[14] L. G. Morris, A. G. Sikora, T. D. Tosteson, and L. Davies, “The increasing incidence of thyroid cancer: the influence of access to care,” Thyroid, vol. 23, no. 7, pp. 885–891, 2013.

[15] R. Udelsman and Y. Zhang, “The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds,” Thyroid, vol. 24, no. 3, pp. 472–479, 2014.

[16] H. Gharib, E. Papini, R. Paschke et al., “American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations,”

Journal of Endocrinological Investigation, vol. 33, no. 5, pp. 287–291, 2010.

[17] R. Smith-Bindman, D. L. Miglioretti, E. Johnson et al., “Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010,” JAMA, vol. 307, no. 22, pp. 2400–2409, 2012.

[18] G. H. Sun, S. DeMonner, and M. M. Davis, “Epidemiological and economic trends in inpatient and outpatient thyroidectomy in the United States, 1996-2006,” Thyroid, vol. 23, no. 6, pp. 727–733, 2013.

[19] A. B. Ergin, S. Saralaya, and L. Olansky, “Incidental papillary thyroid carcinoma: clinical characteristics and prognostic factors among patients with Graves’ disease and euthyroid goiter, Cleveland clinic experience,” American Journal of Otolaryngology, vol. 35, no. 6, pp. 784–790, 2014.

[20] T. S. Wang, P. Goffredo, J. A. Sosa, and S. A. Roman, “Papillary thyroid microcarcinoma: an over-treated malignancy?” World Journal of Surgery, vol. 38, no. 9,pp. 2297–2303, 2014.

[21] B. R. Haugen, E. K. Alexander, K. C. Bible et al., “2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 26, no. 1, pp. 1–133, 2016.

[22] R. V. Lloyd, L. A. Erickson, M. B. Casey et al., “Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma,” The American Journal of Surgical Pathology, vol. 28, no. 10, pp. 1336–1340, 2004.

[23] H. M. Verkooijen, G. Fioretta, J. C. Pache et al., “Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland,” Cancer Causes & Control, vol. 14, no. 1, pp. 13–17, 2003.

[24] Y. E. Nikiforov, R. R. Seethala, G. Tallini et al., “Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors,” JAMA Oncology, vol. 2, no. 8, pp. 1023–1029, 2016.

[25] H. Lim, S. S. Devesa, J. A. Sosa, D. Check, and C. M. Kitahara, “Trends in thyroid cancer incidence and mortality in the United States, 1974-2013,” JAMA, vol. 317, no. 13, pp. 1338–1348, 2017.

[26] D. Williams, “Radiation carcinogenesis: lessons from Chernobyl,” Oncogene, vol. 27, Supplement 2, pp. S9–S18, 2008.

[27] E. Ron, J. H. Lubin, R. E. Shore et al., “Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. 1995,” Radiation Research, vol. 178, no. 2, pp. -AV43–AV60, 2012.

[28] E. Cardis, A. Kesminiene, V. Ivanov et al., “Risk of thyroid cancer after exposure to 131I in childhood,” Journal of the National Cancer Institute, vol. 97, no. 10, pp. 724–732, 2005.

[29] K. Furukawa, D. Preston, S. Funamoto et al., “Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors: 60 years after exposure,” International Journal of Cancer, vol. 132, no. 5, pp. 1222–1226, 2013.

[30] M. N. Nikiforova, J. R. Stringer, R. Blough, M. Medvedovic, J. A. Fagin, and Y. E. Nikiforov, “Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells,” Science, vol. 290, no. 5489, pp. 138–141, 2000.

[31] F. A. Mettler Jr., M. Bhargavan, B. R. Thomadsen et al., “Nuclear medicine exposure in the United States, 2005-2007: preliminary results,” Seminars in Nuclear Medicine,vol. 38, no. 5, pp. 384–391, 2008.

[32] A. Memon, S. Godward, D. Williams, I. Siddique, and K. Al-Saleh, “Dental x-rays and the risk of thyroid cancer: a case  control study,” Acta Oncologica, vol. 49, no. 4, pp. 447–453,2010.

[33] C. K. Jung, M. P. Little, J. H. Lubin et al., “The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 2, pp. E276–E285, 2014.

[34] C. Romei, L. Fugazzola, E. Puxeddu et al., “Modifications in the papillary thyroid cancer gene profile over the last 15 years,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 9, pp. E1758–E1765, 2012.

[35] J. G. Fortner, P. A. George, and S. S. Sternberg, “Induced and spontaneous thyroid cancer in the Syrian (golden) hamster,” Endocrinology, vol. 6, pp. 364–376, 1960.

[36] R. T. Schaller Jr and J. K. Stevenson, “Development of carcinoma of the thyroid in iodine-deficient mice,” Cancer,vol. 19, no. 8, pp. 1063–1080, 1966.

[37] J. Xiang, X. Wang, Z. Wang et al., “Effect of different iodine concentrations on well-differentiated thyroid cancer cell behavior and its inner mechanism,” Cell Biochemistry and Biophysics, vol. 71, no. 1, pp. 299–305, 2015.

[38] E. Clero, F. Doyon, V. Chungue et al., “Dietary iodine and thyroid cancer risk in French Polynesia: a case-control study,” Thyroid, vol. 22, no. 4, pp. 422–429, 2012.

[39] U. Feldt-Rasmussen, “Iodine and cancer,” Thyroid, vol. 11, no. 5, pp. 483–486, 2001.

[40] L. N. Kolonel, J. H. Hankin, L. R. Wilkens, F. H. Fukunaga, and M. W. Hinds, “An epidemiologic study of thyroid cancer in Hawaii,” Cancer Causes & Control, vol. 1, no. 3, pp. 223–234, 1990.

[41] M. Knobel and G. Medeiros-Neto, “Relevance of iodine intake as a reputed predisposing factor for thyroid cancer,”

Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 51, no. 5, pp. 701–712, 2007.

[42] W. Dong, H. Zhang, P. Zhang et al., “The changing incidence of thyroid carcinoma in Shenyang, China before and after universal salt iodization,” Medical Science Monitor, vol. 19,pp. 49–53, 2013.

[43] W. Teng, Z. Shan, X. Teng et al., “Effect of iodine intake on thyroid diseases in China,” The New England Journal of Medicine, vol. 354, no. 26, pp. 2783–2793, 2006.

[44] Z. Shan, L. Chen, X. Lian et al., “Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China: a cross-sectional study in 10 cities,” Thyroid, vol. 26, no. 8, pp. 1125–1130,2016.

[45] T. Sehestedt, N. Knudsen, H. Perrild, and C. Johansen, “Iodine intake and incidence of thyroid cancer in Denmark,” Clinical Endocrinology, vol. 65, no. 2, pp. 229–233, 2006.

[46] C. S. Fuziwara and E. T. Kimura, “High iodine blocks a Notch/miR-19 loop activated by the BRAF(V600E) oncoprotein and restores the response to TGFbeta in thyroid follicular cells,” Thyroid, vol. 24, no. 3, pp. 453–462, 2014.

[47] H. Guan, M. Ji, R. Bao et al., “Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer,” The Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 5, pp. 1612–1617, 2009.

[48] R. Bubenhofer and C. Hedinger, “Thyroid neoplasms before and after the prophylactic supplementation of table salt with iodine,” Schweizerische Medizinische Wochenschrift, vol. 107,no. 21, pp. 733–741, 1977.

[49] E. D. Williams, I. Doniach, O. Bjarnason, and W. Michie, “Thyroid cancer in an iodide rich area: a histopathological study,” Cancer, vol. 39, no. 1, pp. 215–222, 1977.

[50] D. Schmid, G. Behrens, C. Jochem, M. Keimling, and M. Leitzmann, “Physical activity, diabetes, and risk of thyroid cancer: a systematic review and meta-analysis,” European Journal of Epidemiology, vol. 28, no. 12, pp. 945–958, 2013.

[51] C. M. Kitahara, E. A. Platz, L. E. Freeman et al., “Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies,” Cancer Epidemiology, Biomarkers & Prevention, vol. 20, no. 3, pp. 464–472, 2011.

[52] J. Ma, M. Huang, L. Wang, W. Ye, Y. Tong, and H. Wang, “Obesity and risk of thyroid cancer: evidence from a metaanalysis of 21 observational studies,” Medical Science Monitor, vol. 21, pp. 283–291, 2015.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024